Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity*

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Isik, Gözde ^a   van Montfort, Thijs ^a   Boot, Maikel ^a   Cobos Jiménez, Viviana ^b   Kootstra, Neeltje A ^b   Sanders, Rogier W ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANTIGEN STRUCTURE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; GENE ORDER; GLYCOSYLATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULIN G; MONOCYTES; MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84875674153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060126     Document Type: Article

References (63)

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286 101056/NEJMoa1113425 [doi].
2. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540 101128/JVI.75.12.5526-5540.2001 [doi].
3. Bontjer I, Melchers M, Eggink D, David K, Moore JP, et al. (2010) Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem 285: 36456-36470. M110.156588 [pii];10.1074/jbc.M110.156588 [doi].
4. Burton DR, Desrosiers RC, Doms RW, Koff WC, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236 101038/ni0304-233 [doi];ni0304-233 [pii].
5. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, et al. (1997) Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71: 9808-9812.
6. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578. ni.1746 [pii];10.1038/ni.1746 [doi].
7. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L, (2003) Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77: 2310-2320.
8. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343. nature10696 [pii];10.1038/nature10696 [doi].
9. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103. science.1213256 [pii];10.1126/science.1213256 [doi].
10. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
11. Scanlan CN, Pantophlet R, Wormald MR, Ollmann SE, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
12. Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, et al. (2012) Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res Hum Retroviruses 28: 206-214 101089/aid.2011.0101 [doi].
13. Chung NP, Matthews K, Klasse PJ, Sanders RW, Moore JP (2012) HIV-1 gp120 Impairs the Induction of B Cell Responses by TLR9-Activated Plasmacytoid Dendritic Cells. J Immunol. jimmunol.1201905 [pii];10.4049/jimmunol.1201905 [doi].
14. Kumar R, Tuen M, Li H, Tse DB, Hioe CE (2011) Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 29: 9064-9074. S0264-410X(11)01464-2 [pii];10.1016/j.vaccine.2011.09.057 [doi].
15. Martinelli E, Cicala C, Van RD, Goode DJ, Macleod K, et al. (2007) HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104: 3396-3401 0611353104 [pii];10.1073/pnas.0611353104 [doi].
16. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515-2528 805/2515 [pii];10.1128/JVI.80.5.2515-2528.2006 [doi].
17. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3: e169 07PLPA-RA-0438 [pii];10.1371/journal.ppat.0030169 [doi].
18. Parren PW, Burton DR, Sattentau QJ, (1997) HIV-1 antibody-debris or virion? Nat Med 3: 366-367.
19. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627-643.
20. Dey AK, David KB, Lu M, Moore JP (2009) Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385: 275-281. S0042-6822(08)00802-7 [pii];10.1016/j.virol.2008.12.009 [doi].
21. Pancera M, Wyatt R (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332: 145-156. S0042-6822(04)00727-5 [pii];10.1016/j.virol.2004.10.042 [doi].
22. Si Z, Phan N, Kiprilov E, Sodroski J (2003) Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 19: 217-226 101089/088922203763315722 [doi].
23. van Montfort T, Melchers M, Isik G, Menis S, Huang PS, et al. (2011) A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J Biol Chem 286: 22250-22261. M111.229625 [pii];10.1074/jbc.M111.229625 [doi].
24. Just U, Friel J, Heberlein C, Tamura T, Baccarini M, et al. (1993) Upregulation of lineage specific receptors and ligands in multipotential progenitor cells is part of an endogenous program of differentiation. Growth Factors 9: 291-300.
25. Denecker G, Vandenabeele P, Grooten J, Penning LC, Declercq W, et al. (1997) Differential role of calcium in tumour necrosis factor-mediated apoptosis and secretion of granulocyte-macrophage colony-stimulating factor in a T cell hybridoma. Cytokine 9: 631-638. S1043-4666(97)90218-0 [pii];10.1006/cyto.1997.0218 [doi].
26. Klein B, Le Bousse-Kerdiles C, Smadja-Joffe F, Pragnell I, Ostertag W, et al. (1982) A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV). Exp Hematol 10: 373-382.
27. Deresinski SC, (1999) Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection. AIDS 13: 633-643.
28. Ghirelli C, Zollinger R, Soumelis V (2010) Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 115: 5037-5040. blood-2010-01-266932 [pii];10.1182/blood-2010-01-266932 [doi].
29. Von Feldt JM, Kieber-Emmons T, Weiner DB, Ugen KE, Williams WV, (1992) Molecular structure and granulocyte/macrophage colony-stimulating factor activity. DNA Cell Biol 11: 183-191.
30. van Anken E, Sanders RW, Liscaljet IM, Land A, Bontjer I, et al. (2008) Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Mol Biol Cell 19: 4298-4309. E07-12-1282 [pii];10.1091/mbc.E07-12-1282 [doi].
31. Cebon J, Nicola N, Ward M, Gardner I, Dempsey P, et al. (1990) Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity. J Biol Chem 265: 4483-4491.
32. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, et al. (2002) Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76: 2606-2616.
33. Crooks ET, Tong T, Osawa K, Binley JM (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: 5825-5839. JVI.00154-11 [pii];10.1128/JVI.00154-11 [doi].
34. Parren PW, Burton DR, (1997) Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy. Chem Immunol 65: 18-56.
35. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875-8889.
36. Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, et al. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401: 236-247. S0042-6822(10)00128-5 [pii];10.1016/j.virol.2010.02.019 [doi].
37. Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, et al. (2011) A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology. In press.
38. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, et al. (2012) Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86: 2488-2500. JVI.06259-11 [pii];10.1128/JVI.06259-11 [doi].
39. Chroneos Z, Shepherd VL, (1995) Differential regulation of the mannose and SP-A receptors on macrophages. Am J Physiol 269: L721-L726.
40. Cobos Jiménez V, Booiman T, de Taeye SW, van Dort KA, Rits MA, et al. (2012) Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep 2: 763 101038/srep00763 [doi].
41. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686. S1471-4906(04)00295-9 [pii];10.1016/j.it.2004.09.015 [doi].
42. McCormick AL, Thomas MS, Heath AW (2001) Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. J Infect Dis 184: 1423-1430. JID010413 [pii];10.1086/324371 [doi].
43. Nimal S, McCormick AL, Thomas MS, Heath AW (2005) An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming. Vaccine 23: 3984-3990. S0264-410X(05)00335-X [pii];10.1016/j.vaccine.2005.01.160 [doi].
44. Nimal S, Heath AW, Thomas MS (2006) Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 24: 3298-3308. S0264-410X(06)00035-1 [pii];10.1016/j.vaccine.2006.01.020 [doi].
45. Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, et al. (2009) The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114: 1289-1298. blood-2008-12-164004 [pii];10.1182/blood-2008-12-164004 [doi].
46. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, et al. (2010) Molecular basis of cytokine receptor activation. IUBMB Life 62: 509-518 101002/iub.350 [doi].
47. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258. S0092-8674(01)00449-4 [pii].
48. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, et al. (2011) RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12: 560-567. ni.2027 [pii];10.1038/ni.2027 [doi].
49. Shanafelt AB, Kastelein RA, (1989) Identification of critical regions in mouse granulocyte-macrophage colony-stimulating factor by scanning-deletion analysis. Proc Natl Acad Sci U S A 86: 4872-4876.
50. Moonen P, Mermod JJ, Ernst JF, Hirschi M, DeLamarter JF, (1987) Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast or animal cells. Proc Natl Acad Sci U S A 84: 4428-4431.
51. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, et al. (2012) Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8: e1002797 101371/journal.ppat.1002797 [doi];PPATHOGENS-D-12-01032 [pii].
52. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, et al. (1995) Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69: 5723-5733.
53. Rozwarski DA, Diederichs K, Hecht R, Boone T, Karplus PA (1996) AID-PROT6>3.0.CO;2-D [pii];10.1002/(SICI)1097-0134(199611)26:3<304::AID-PROT6>3.0.CO;2-D [doi].
54. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
55. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, et al. (2003) Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325: 325-335. S0022283602012329 [pii].
56. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110. JVI.00966-10 [pii]; doi:10.1128/JVI.00966-10.
57. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: 11483-11488 100460010 [pii]; doi:10.1073/pnas.1004600107.
58. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 117874 [pii]; doi:10.1126/science.1178746.
59. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. nature11519 [pii]; doi:10.1038/nature11519.
60. Cutalo JM, Deterding LJ, Tomer KB (2004) Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom 15: 1545-1555. S1044-0305(04)00480-5 [pii]; doi:10.1016/j.jasms.2004.07.008.
61. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
62. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204. bi000432m [pii].
63. Forno G, Bollati FM, Oggero M, Kratje R, Etcheverrigaray M, et al.(2004) N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. Eur J Biochem 271: 907-919 3993 [pii].